Agonistic antibody to TRAIL-R1 (Mapatumumab) and low dose Bortezomib induce apoptosis in multiple myeloma while preserving dendritic cell function

被引：0
|
作者：
Neeson, Paul
Chen, Karen
Tai, Tsin
Shin, Amanda
Tainton, Kellie
Fielding, Kate
Davis, Joanne
Prince, H.
Humphreys, Robin
Ritchie, David
机构：
[1] Peter MacCallum Canc Inst, Melbourne, Vic 3000, Australia
[2] Human Genome Sci, Rockville, MD USA
来源：
CANCER RESEARCH | 2009年 / 69卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3240
引用
收藏
页数：1
相关论文
共 19 条
  • [1] Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody resistant NSCLC cell lines when treated in combination with bortezomib
    Luster, Troy
    Carrell, Jeffrey
    Humphreys, Robin
    CANCER RESEARCH, 2009, 69
  • [2] Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody-resistant NSCLC cell lines when treated in combination with bortezomib
    Luster, Troy A.
    Carrel, Jeffrey A.
    McCormick, Kathy
    Sun, David
    Humphreys, Robin
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (02) : 292 - 302
  • [3] A phase I study with the agonistic TRAIL-R1 antibody, mapatumumab, in combination with gemcitabine and cisplatin
    Oldenhuis, C.
    Mom, C.
    Sleijfer, S.
    Gietema, J. A.
    Fox, N. L.
    Corey, A.
    Eskens, F.
    Loos, W.
    de Vries, E. G.
    Verweij, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [4] Mapatumumab, A TRAIL Receptor 1 Agonist Antibody, Induces Apoptosis in Bortezomib Resistant Multiple Myeloma.
    Ghoshal, Pushpankur
    Chitta, Kasyapa
    Vujcic, Slavoljub
    Gaddy, Jacquelyne
    Miles, Kiersten M.
    Stein, Leighton
    Sher, Taimur
    Lee, Kelvin P.
    Chanan-Khan, Asher A.
    BLOOD, 2009, 114 (22) : 1106 - 1107
  • [5] Mapatumumab, a Fully Human Agonistic Monoclonal Antibody That Targets TRAIL-R1, in Combination with Gemcitabine and Cisplatin: a Phase I Study
    Mom, Constantijne H.
    Verweij, Jaap
    Oldenhuis, Corina N. A. M.
    Gietema, Jourik A.
    Fox, Norma Lynn
    Miceli, Rene
    Eskens, Ferry A. L. M.
    Loos, Walter J.
    de Vries, Elisabeth G. E.
    Sleijfer, Stefan
    CLINICAL CANCER RESEARCH, 2009, 15 (17) : 5584 - 5590
  • [6] Targeting apoptosis: preclinical and early clinical experience with mapatumumab, an agonist monoclonal antibody targeting TRAIL-R1
    Moretto, Patricia
    Hotte, Sebastien J.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2009, 18 (03) : 311 - 325
  • [7] Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase 1 study in patients with advanced solid malignancies
    Mom, C. H.
    Sleijfer, S.
    Gietema, J. A.
    Fox, N. L.
    Piganeau, C.
    Lo, L.
    Uges, D. R. A.
    Loos, W.
    de Vries, E. G. E.
    Verweij, J.
    EJC SUPPLEMENTS, 2006, 4 (12): : 63 - 63
  • [8] Mapatumumab, a Fully Human Agonistic Monoclonal Antibody That Targets TRAIL-R1, in Combination with Gemcitabine and Cisplatin: A Phase I Study (vol 15, pg 5584, 2009)
    Mom, C. H.
    Verweij, J.
    Oldenhuis, C. N. A. M.
    CLINICAL CANCER RESEARCH, 2009, 15 (21) : 6744 - 6744
  • [9] Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer
    T Trarbach
    M Moehler
    V Heinemann
    C-H Köhne
    M Przyborek
    C Schulz
    V Sneller
    G Gallant
    S Kanzler
    British Journal of Cancer, 2010, 102 : 506 - 512
  • [10] Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer
    Trarbach, T.
    Moehler, M.
    Heinemann, V.
    Koehne, C-H
    Przyborek, M.
    Schulz, C.
    Sneller, V.
    Gallant, G.
    Kanzler, S.
    BRITISH JOURNAL OF CANCER, 2010, 102 (03) : 506 - 512
12